Italia markets closed

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
135,60+0,25 (+0,18%)
Al 12:10PM EDT. Mercato aperto.

Jazz Pharmaceuticals plc

Waterloo Exchange
Fifth Floor Waterloo Road
Dublin 4
Ireland
353 1 634 7800
http://www.jazzpharma.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno1.940

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Bruce C. CozaddCo-Founder, Chairman & CEO2,48M823,12k1964
Mr. Daniel N. Swisher Jr.Pres1,37MN/D1963
Ms. Renee D. GalaExec. VP & CFO924,52kN/D1972
Dr. Robert Iannone M.D.Exec. VP of R&D and Chief Medical Officer1,05MN/D1967
Ms. Kim SablichExec. VP & GM of North America869,48kN/D1969
Mr. Christopher John ToveyExec. VP, COO and MD of Europe & InternationalN/DN/D1965
Ms. Patricia CarrVP of Fin. & Principal Accounting OfficerN/DN/D1971
Dr. Finbar Larkin Ph.D.Sr. VP of Technical OperationsN/DN/D1958
Ms. Andrea N. FlynnVP & Head of Investor RelationsN/DN/DN/D
Ms. Neena M. Patil J.D.Chief Legal Officer and Sr. VP of Legal & Corp. AffairsN/DN/D1975
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.

Governance aziendale

L'ISS Governance QualityScore di Jazz Pharmaceuticals plc al 26 settembre 2021 è 4. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 3; diritti degli azionisti: 4; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.